14-day Premium Trial Subscription Sign Up For FreeGet Free

Acceleron Pharma Inc. Stock Forecast NASDAQ:XLRN

$178.75 (0%)

Volume: 0

Closed: Jan 19, 2022

Hollow Logo Score: 0.000

Acceleron Pharma Inc. Stock Forecast

$178.75 (0%)

Volume: 0

Closed: Jan 19, 2022

Score Hollow Logo 0.000

Acceleron Pharma Inc. Company Profile

128 Sidney Street

Cambridge MA 02139



Industry: Biotechnology

Sector: Healthcare

Acceleron Pharma Inc.


Acceleron Pharma Inc., a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of protein therapeutics for cancer and rare diseases. It is developing sotatercept to treat patients with chronic kidney disease, including mineral-bone disorder, vascular calcification, and anemia; and luspatercept to treat anemia and associated complications in patients with myelodysplastic syndromes and beta-thalassemia. The company is also developing dalantercept therapeutic candidate to treat renal cell carcinoma; and ACE-083 to promote muscle growth and function in specific treated muscles. It has collaboration, license, and option agreement with Celgene Corporation. The company was formerly known as Phoenix Pharma, Inc. Acceleron Pharma Inc. was founded in 2003 and is headquartered in Cambridge, Massachusetts.

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE